Rationale: Malignant myopericytoma is extremely rare, with a few cases described in the English literature.
Introduction
The concept, myopericytoma, was described for the first time by . [1] The World Health Organization (WHO) officially recognized the term "myopericytoma" in 2002 and referred to it as a member of the pericytic group in the Classification of Tumors of Soft Tissue and Bone. [2] Myopericytoma is a rare tumor that is predominantly located in the skin and superficial soft tissues of extremities, such as arm, thigh, leg, foot, and neck. [3] Most myopericytomas are benign in nature. Malignant myopericytoma is exceptionally rare, with only 8 cases described in the literature. [4] [5] [6] [7] This study reported the ninth case, which is the first in the left armpit with a long history of 31 years.
Case report
A 56-year-old man presented to The Shaanxi Province Oncology Hospital with "an enlarging painful mass in his left armpit" in 2012. He had initially presented 31 years earlier with a painless nodule in the subcutaneous tissue of the left armpit. No other clinical symptoms were present at that time. The patient did not receive any treatment for 31 years. The following years, the nodule grew slowly. The mass expanded rapidly and ulcerated in the last year. Two months ago, the patient suffered from pain in the left shoulder during sports. At the same time, obvious symptoms of cancer cachexia, including emaciation, anemia, and lower extremity edema, were appeared. He had no medical history of surgery and trauma in the left armpit.
Physical examination showed an ulcerated and smelly mass in the left armpit (Fig. 1) . The computer tomography (CT) scan demonstrated a mass of 6.1 Â 5.3 cm 2 in the left armpit (Fig. 2) , with no evidence of metastasis according to the chest CT, abdominal ultrasound, and emission CT. Other tests showed anemia and hypoproteinemia. He underwent biopsy of an enlarging mass, and a diagnosis of malignant myopericytoma was rendered (Fig. 3) . Immunohistochemical analysis revealed that the tumor had strong cytoplasmic reactivity for musclespecific actin (SMA) and was negative for desmin and human melanoma black-45 (HMB-45).
The patient received 2 standard courses of theprubicin (THP) combined with ifosfamide (IFO) chemotherapy regimen (THP: 60 mg on day 1; IFO: 2 g on days 1-3) with no tumor response according to the CT findings. He subsequently underwent complete resection by a surgical technologist. At the time of surgery, the mass was found to be arising from the axillary vein (Fig. 4) . Postoperative pathology indicated that the tumor size was 6.5 Â 5.5 cm 2 , the margin was negative, and the lymph node was negative. After the surgery, clinical symptoms gradually disappeared. The follow-up was performed at 3 months in the first year, 6 months in the second year, and 1 year after 3 years. The last follow-up was March 2017. According to the clinical symptoms and imaging and laboratory tests, the patient did not show recurrence and metastasis during the follow-up for 5 years ( This case report was approved by the ethics committee, and informed consent form was obtained from the patient.
Discussion
In 1996, Requena et al [8] suggested "myopericytoma" as an alternative name for some cutaneous adult myofibromas. Later, in 1998, Granter et al [9] described a group of vascular tumors, including tumors with phenotypic features of cutaneous adult myofibroma, glomus tumors, glomangiopericytoma, and myopericytoma. The term "myopericytoma" was officially recognized by the WHO Classification of Tumors of Soft Tissue and Bone in 2012. [10] Myopericytoma is one of the members of the perivascular tumor family, including myofibroma, angioleiomyoma, glomus tumor, and myopericytoma. [11] So far, the cause of myopericytomas is unclear. Some authors suggested that the cause seemed to be related to the Epstein-Barr virus. [12] The immunohistochemical analysis showed that SMA was positive, supporting a pericytic/myofibroblastic differentiation. Desmin positivity was seen in rare cases. Clinically, most myopericytomas are seen in middle-aged adults. Although they are generally considered benign with an indolent clinical course, they have the potential to recur locally with distant metastases. [13] Malignant myopericytoma are exquisitely rare. They show aggressive clinical behavior and poor prognosis. Only 8 cases have been reported in the literature to date. The largest series was reported by McMenamin and Fletcher [14] in 2002 and included 5 patients. Mentzel et al [15] reported 1 patient in 2006, and Mainville et al [16] reported 1 patient in 2012. Holling et al [17] reported 1 patient in 2015. Out of the 8 reported patients, 4 were males and 4 were females. The tumors were located in extremities, neck, mediastinum, heart, and spine. All the patients underwent surgical excision. Four patients did not show recurrence, including 3 wide excisions and 1 marginal excision and radiotherapy. Four patients developed metastases, and 3 died of disease within 1 year. The clinical features of the 8 previously reported cases in addition to this one are summarized in Table 1 . This study reported a case of malignant myopericytoma arising in the left armpit, the histopathologic and immunophenotypic features of which were similar to those previously reported, but clinical features and anatomic site were different. This case had the longest clinical history reported in the literature till now, with obvious cancer cachexia symptoms. No standard treatment exists for malignant myopericytoma. The patient received 2 cycles of THP combined with IFO chemotherapy regimen with no tumor response. Consequently, chemotherapy might not be necessary. Complete surgical excision of the lesion might be the only potentially curative treatment, and the timing and frequency of follow-up are essential.
Conclusion
Myopericytoma are generally considered benign with an indolent clinical course, and a few reports have described malignant myopericytoma in the literature. The clinical and pathologic features of these cases of malignant myopericytoma were summarized in this study. No standard treatment is available, and complete surgical excision of the lesion may be the only potentially curative treatment. The efficacy of chemotherapy and radiation is uncertain. However, the currently reported rare cases may not be sufficient to allow the clinical outcome to be fully evaluated, requiring the involvement of large samples. Mentzel et al [15] F/61
Lower leg Chen et al. Medicine (2017) 96:49 www.md-journal.com
